Sep 2026· Journal of Radiation Research· 0 citations· 23 references
Medicine
TL;DR
Risk-adapted SBRT with increased fractionation demonstrated encouraging LC while maintaining an acceptable toxicity profile for central and ultracentral lung tumors, however, the risk of severe toxicity remains, requiring careful patient selection and optimized OAR dose constraints.
Abstract
This study evaluated the clinical outcomes and safety of risk-adapted stereotactic body radiotherapy (SBRT) using non-standard fractionation schedules for lung tumors adjacent to organs at risk (OARs). We retrospectively analyzed 81 consecutive patients (92 lesions, 2008-25) who received SBRT, including repeat irradiation outside prior fields, with non-standard regimens (56 Gy/7 fractions [fr], 50 Gy/10 fr, 60 Gy/10 fr, 48 Gy/6 fr and 35 Gy/5 fr). Endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), locoregional progression-free survival, local control (LC) and Grade ≥ 3 adverse events. At a median follow-up of 22.2 months (IQR, 12.1-42.9), the median OS was 26.4 months (95% CI: 17.2-43.0), with 1- and 3-year OS rates of 78.6% and 44.1%, respectively. The median PFS was 14.5 months (95% CI: 9.4-21.1), and the median CSS was 43.7 months (95% CI, 22.7-64.4). Median LC was not reached. No significant survival disparities were identified between primary and metastatic cohorts. Grade ≥ 3 toxicities occurred in 10 patients (12.3%), including two Grade 5 events. The 3-year cumulative incidence of Grade ≥ 3 toxicity in ultracentral tumors was 12.6%, with no significant differences among groups. In conclusion, risk-adapted SBRT with increased fractionation demonstrated encouraging LC while maintaining an acceptable toxicity profile for central and ultracentral lung tumors. However, the risk of severe toxicity remains, requiring careful patient selection and optimized OAR dose constraints.
Stereotactic body radiotherapy (SBRT/SABR) is a curative treatment for early-stage lung cancer in patients unsuitable for surgery. While tumor laterality is routinely considered in surgical decision-making, its relevance to outcomes after SBRT remains unclear. This study evaluated clinical outcomes after SBRT and...
P. Burkoň, I. Selingerová, M. Slávik et al.· Radiation Oncology· 0 citations
PURPOSE
This prospective single-center cohort study evaluated outcomes and toxicity after ablative stereotactic magnetic resonance imaging (MRI)-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC).
MATERIALS AND METHODS
Patients with LAPC treated within the MOMENTUM pr...
Pia Braagaard Hartfelt, A. Bisgaard, M. Ejlsmark et al.· Radiotherapy and Oncology· 0 citations
Purpose Recurrent or second primary head and neck cancer (rsHNC) presents a radiotherapeutic challenge due to limited tolerance of previously irradiated tissues. These patients could benefit from dose painting (DP), which focuses on delivering maximal dose to areas of high tumor burden while respecting dose constraints...
E. Dale, M. Evensen, C. D. Amdal et al.· Frontiers in Oncology· 0 citations
Objective To evaluate the efficacy and safety of low-dose hypofractionated radiotherapy (LDHRT) for liver metastases when combined with immunotherapy. Methods Patients with liver metastases receiving immunotherapy were enrolled in this study at Changzhou Second People’s Hospital from January 2019 to May 2025 (Ethics Ap...
Lan-Qun Qin, Yan-Shuang Wei, Li Tao et al.· OncoTargets and Therapy· 0 citations
OBJECTIVES
Optimal dose fractionation of stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer (NSCLC) remains unclear. This population-based study compares outcomes and toxicities of single-fraction (SF) versus multi-fraction (MF) SABR.
METHODS
All patients in British Columbia, Canada w...
K. A. Aguirre-Meneses, S. Baker, J. Callueng et al.· Radiotherapy and Oncology· 0 citations
OBJECTIVE
This study aimed to escalate the dose to the residual primary tumor with an adaptive stereotactic body radiotherapy (SBRT) boost after concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer (NSCLC), and to explore, within this cohort, whether a higher cumulative dose to the re...
Esin Kiraz, C. Eroğlu, M. Gundog et al.· International Journal of Rad...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.